

# Neuromodulation of sleep disorders: a new neurophysiological-based approach to restless legs syndrome

<b>Submission date</b> 08/02/2024	<b>Recruitment status</b> Suspended	<input checked="" type="checkbox"/> Prospectively registered
		<input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 13/02/2024	<b>Overall study status</b> Suspended	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 17/02/2025	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Restless Legs Syndrome (RLS) is a common sleep disorder characterized by an urge to move the legs that is responsive to movement (particularly during rest), periodic leg movements during sleep, and disrupted sleep. RLS is rather complex and not fully understood yet. Although the dopaminergic pathways play a crucial role, other neurotransmitters (brain chemicals) seem to contribute, such as the adenosinergic system. However, there isn't enough evidence yet of direct involvement in RLS patients. Transcranial magnetic stimulation (TMS) is a non-invasive method used to study brain activity and chemistry in various neurological conditions, including sleep disorders. This study aims to see how dipyridamole, which enhances adenosinergic transmission, and caffeine, which blocks adenosine receptors, affect TMS measurements of brain activity.

### Who can participate?

Adult patients aged 18-65 years with primary RLS

### What does the study involve?

Each participant will receive a single oral dose of dipyridamole, caffeine, or a placebo in a random sequence. Drug administration will occur during three different TMS sessions in the late afternoon with a sufficient wash-out period between sessions.

### What are the possible benefits and risks of participating?

Although the study has mainly a diagnostic purpose, the results will also support the design of new evidence-based drugs and other treatment approaches.

### Where is the study run from?

Oasi Research Institute-IRCCS (Italy)

### When is the study starting and how long is it expected to run for?

March 2024 to February 2025

Who is funding the study?  
Ministry of Health (Italy)

Who is the main contact?  
Dr Giuseppe Lanza, giuseppe.lanza1@unict.it

## Contact information

### Type(s)

Scientific, Principal investigator

### Contact name

Prof Giuseppe Lanza

### ORCID ID

<https://orcid.org/0000-0002-5659-662X>

### Contact details

Via Conte Ruggero, 73  
Troina  
Italy  
94018  
+39 (0)935 936930  
glanza@oasi.en.it

### Type(s)

Public

### Contact name

Dr Rosa Di Giorgio

### ORCID ID

<https://orcid.org/0000-0002-5659-662X>

### Contact details

Via Conte Ruggero, 73  
Troina  
Italy  
94018  
+39 (0)935 936374  
dir.scien@oasi.en.it

## Additional identifiers

## Study information

### Scientific Title

Targeting the adenosinergic system in restless legs syndrome: a “proof-of-concept” placebo-controlled transcranial magnetic stimulation-based protocol

## **Acronym**

RLS-TMS

## **Study objectives**

In this study protocol, the aim is to investigate the effects of dipyridamole (a well-known enhancer of adenosinergic transmission) and caffeine (an adenosine receptor antagonist) on measures of cortical excitation and inhibition in response to transcranial magnetic stimulation (TMS) in patients with primary restless legs syndrome (RLS). Initially, the researchers will assess cortical excitability using both single- and paired-pulse TMS in patients with RLS. Then, based on the measures obtained, they will explore the effects of dipyridamole and caffeine, in comparison to placebo, on various TMS parameters related to cortical excitation and inhibition. Finally, the researchers will evaluate the psycho-cognitive performance of RLS patients to screen them for cognitive impairment and/or mood-behavioral dysfunction, thus aiming to correlate psycho-cognitive findings with TMS data.

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

approved 25/10/2016, Comitato Etico dell'IRCCS Associazione Oasi Maria SS (Via Conte Ruggero, 73, Troina, 94018, Italy; +39 (0)935 936374; dir.scien@oasi.en.it), ref: 2016/CE-IRCCS-OASI/1

## **Study design**

Double-blind randomized cross-over exploratory design

## **Primary study design**

Interventional

## **Study type(s)**

Diagnostic, Efficacy

## **Health condition(s) or problem(s) studied**

Non-invasive exploration of the pathophysiology and neurochemistry of restless legs syndrome

## **Interventions**

Each participant will receive dipyridamole, caffeine, or a placebo in a random sequence determined by computer-generated random numbers. The administration will occur during three different TMS sessions in the late afternoon (in accordance with the circadian distribution of RLS symptoms), with a sufficient wash-out period (at least 2 times the half-life of each substance) between sessions. To enhance the randomness of the sequence, planned restrictions will be unavailable to the contributors enrolling participants or assigning interventions. The allocation sequence will be implemented using sequentially numbered, opaque, sealed envelopes. Blinding of trial participants, outcome assessors, and data analysts will be maintained also after assignment to interventions.

Dipyridamole arm: dipyridamole; dosage given: 75 mg; method and frequency of administration: single oral administration; total duration of treatment: 1 day; follow-up: none.

Caffeine arm: caffeine; dosage given: 200 mg; method and frequency of administration: single oral administration; total duration of treatment: 1 day; follow-up: none.

## **Intervention Type**

Mixed

### **Primary outcome(s)**

1. Resting motor threshold (%)
2. Cortical silent period (ms)
3. Latency and amplitude of the motor evoked potentials (ms/mV)
4. Central motor conduction time (ms)
5. Intracortical inhibition (ratio)
6. Intracortical facilitation (ratio)

All these measures, elicited through specific transcranial magnetic stimulation (TMS) protocols, will be performed at baseline and 1 hour after the administration of dipyridamole, caffeine, or placebo.

### **Key secondary outcome(s)**

Correlation between TMS metrics (please see those listed among primary outcome measures) and psycho-cognitive assessment, in order to screen RLS patients for cognitive impairment and /or mood-behavioral dysfunction:

1. Vocabulary assessed using the Wechsler Adult Intelligence Scale
2. Presence of sleep disorders assessed using the Global Sleep Assessment Questionnaire
3. Sleep quality assessed using the Pittsburgh Sleep Quality Index
4. Severity of depression assessed using the Beck Depression Inventory II
5. State and trait anxiety assessed using the State-Trait Anxiety Inventory

Correlations will be performed at baseline only, since psychocognitive tests are not repeated after 1 hour.

## **Completion date**

28/02/2025

## **Eligibility**

### **Key inclusion criteria**

1. Age 18-65 years
2. Diagnosis of RLS according to the latest criteria by the International RLS Study Group
3. RLS symptoms on 3 or more days per week for at least 3 months
4. International RLS Rating Scale (IRLS-RS) score >15 (i.e., moderate symptomatology, at least)
5. Normal brain magnetic resonance imaging (MRI) and upper limb electromyography (EMG), including the study of the F-waves
6. Women of childbearing potential must have a negative pregnancy test and agree not to become pregnant during the whole experimental procedure
7. Personally signed and dated informed consent obtained before any procedure. All personal information about potential and enrolled participants will be collected and maintained, in order to protect confidentiality before, during, and after the whole procedure

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

65 years

**Sex**

All

**Key exclusion criteria**

1. Drug intake affecting cortical excitability or cognitive performance, including those used for RLS
2. Mini Mental State Examination score <24
3. Any major psychiatric disease
4. Other neurological or sleep disorders
5. Severe, untreated, acute, or not compensated medical illness
6. Any secondary form of RLS (i.e. renal failure, anemia, low serum iron and ferritin levels, pregnancy, peripheral neuropathy, etc.)
7. Contraindication to dipyridamole and/or caffeine intake
8. Any condition precluding MRI or TMS execution, such as the presence of a cardiac pacemaker, defibrillator, or mechanical valve, presence of non-compatible joint prostheses, previous neurosurgical procedures, and, for TMS only, seizure or history of epilepsy. A conventional EEG will be also performed in order to exclude a predisposition to seizure.

**Date of first enrolment**

01/03/2024

**Date of final enrolment**

28/02/2025

## Locations

**Countries of recruitment**

Italy

**Study participating centre**

**Oasi Research Institute-IRCCS**

Via Conte Ruggero, 73

Troina

Italy

94018

## Sponsor information

**Organisation**

Oasi Research Institute-IRCCS

**Funder(s)****Funder type**

Government

**Funder Name**

Ministero della Salute

**Alternative Name(s)**

Italian Ministry of Health, Italy Ministry of Health, Ministry of Health of Italy, Ministry of Health - Italy, Ministry of Health, Italy

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

Italy

**Results and Publications****Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study will be available upon request. This study (version v.1.0\_14/07/2020) received approval from the Research Ethics Committee "CE IRCCS Sicilia – Oasi Maria SS." on October 25, 2016 (Approval ID: 2016/CE-IRCCS-OASI/1). It adheres to SPIRIT (Standard Protocol Items for Randomized Trials) recommendations in a clinical trial protocol and related documents. Any protocol amendments or relevant modifications (such as changes to eligibility criteria, outcomes, and analyses) will be communicated to relevant parties, including investigators, the Research Ethics Committee, trial participants, trial registries, journals, and regulators. The recruitment period for this study will range from March 01, 2024, to February 28, 2025. Written informed consent will be signed by all subjects prior to their inclusion in the study; additional consent provisions for participant data collection and use will be obtained, if necessary. Authorship eligibility of protocol contributors will follow the guidelines of the International Committee of Medical Journal Editors (ICMJE).

The name and e-mail address of the investigator/body who should be contacted for access to the datasets: "Scientific Secretary of the Oasi Research Institute-IRCCS, Troina (Italy); e-mail address: dir.scien@oasi.en.it". The type of data that will be shared: "Clinical-demographic, psycho-cognitive, and TMS data". Dates of availability: "Currently not known, presumably after June 2025". Whether consent from participants was required and obtained: "Written informed

consent will be signed by all subjects prior to the inclusion in the study; additional consent provisions for participant data collection and use will be obtained, if necessary.". Comments on data anonymization: "Data could not be fully anonymized, although they will be pseudonymized and safely stored".

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		10/05/2024	14/05/2024	Yes	No